Relapse Multiple Myeloma Clinical Trial
Official title:
Clinical Trial for the Safety and Efficacy of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy
Clinical trial for the safety and efficacy of CS1-targeted CAR-T Cells therapy for relapsed multiple myeloma after BCMA CAR-T cells therapy
This is a single arm, open-label, single-center study. This study is indicated for relapsed CS1+ multiple myeloma, the selections of dose levels and the number of subjects are based on clinical trials of similar foreign products. 50 patients will be enrolled for this trial. Primary objective is to explore the safety, main consideration is dose-related safety. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01775553 -
Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
|
Phase 2 | |
| Recruiting |
NCT05243212 -
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03143049 -
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma
|
Phase 3 | |
| Recruiting |
NCT04302324 -
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
|
Phase 2 | |
| Recruiting |
NCT04143932 -
Multiple Myeloma Turkish Prospective Patient Registry
|
||
| Active, not recruiting |
NCT05113342 -
Descartes-25 in Relapsed/Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05789303 -
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT04918511 -
A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05742217 -
A Study to Learn How Patients With Triple Class Refractory Multiple Myeloma (TCR-MM) Are Treated in Italian Centers for Blood Related Diseases
|
||
| Recruiting |
NCT06138275 -
Elranatamab in R/R Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05431608 -
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05430945 -
A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
|
Early Phase 1 | |
| Not yet recruiting |
NCT06171685 -
Horizon Adaptive Platform Trial Evaluating Therapies in RRMM
|
Phase 2 | |
| Recruiting |
NCT05117008 -
Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT05150522 -
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04355039 -
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
|
Phase 1 | |
| Not yet recruiting |
NCT04670055 -
A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
|
Early Phase 1 | |
| Recruiting |
NCT04004338 -
Carfilzomib in Combination for the Treatment of RR MM
|